Phadia Ab

Cytiva Sweden Ab

Lars Mattsson

Jonas Lidholm

Thomas Lundgren

Key Hyckenberg

Kjell Karlsson

Henrik Everberg

Jens Widehammar

Orjan Grelsson

Enrique Napoleon Carredano

Roger Lundqvist

Helena Skoglar

Gunnar Malmquist

Mikael Berg

Therese Westman

Jenny Dunker

Mikael Carlsten

Håkan Larsson

Linda Mathiasson

Sara Sendabo

Örjan Grelsson

Dan Andersson

Ulrica Olsson

Ioana Erlandsson

The present invention relates to a method for optimizing a bioprocess purification system comprising a bioreactor configured to provide a harvest comprising a target composition, and a purification process arranged downstream the bioreactor and being configured for purification of the harvest to produce a target product having a desired characteristics. The method comprising: a) detecting () at least one quality attribute indicative of characteristics of the target product in a downstream process, b) identifying () correlations between the at least one quality attribute measured in the downstream process and parameters to control a cell culture process in the bioreactor, and c) controlling () the cell culture process to meet the desired characteristics based on the identified correlations, whereby the target characteristics is within a p re-determined range.

Method in bioprocess purification system

A chromatography system arranged to perform automated chromatography column efficiency testing for a specific column to determine efficiency parameters and to further provide guidance to the user. The system has a controller arranged to automatically access data to enable the calculation of a column compression plate height, said data being derived from at least stored parameters of the specific column and the resin to be used in the column, to calculate the efficiency of the column.

Chromatography system

The present invention relates to a computer-implemented method for controlling preparation of a liquid mixture comprising an acid and its conjugate base or a base and its conjugate acid. The method comprises obtaining (S) a composition for the liquid mixture to be prepared and determining (S) a plurality of settings for controlling a preparation of the liquid mixture in one or more automated processes. The plurality of settings are provided (S) to one or more control systems of the one or more automated processes. The present invention also relates to a buffer tool configured to perform the computer-implemented method, a buffer management system comprising the buffer tool, and a computer readable storage medium (), having stored thereon a computer program which, when executed in a buffer tool, causes execution of the computer-implemented method.

Control of a buffer preparation process

The present invention relates to a liquid chromatography system configured to operate with at least one column and configured for purification of a sample comprising a target product using a predefined process. The liquid chromatography system comprises a controller configured to: control the operation of the chromatography system to run the predefined process; retrieve column data accessible from a data storage, the column data being specific to each column; and adapt at least one process parameter of the predefined process for each column based on column data. Whereby the predefined process is adapted to each column to obtain the target product and maintain the performance of the liquid chromatography system.

Apparatus, method, and computer program product for adapting a predefined liquid chromatography process

The present invention relates to a liquid chromatography system () configured to operate with at least one column and configured for purification of a sample comprising a target product using a predefined process. The liquid chromatography system comprises a controller () configured to: control the operation of the chromatography system to run the predefined process; retrieve column data accessible from a data storage, the column data being specific to each column; and adapt at least one process parameter of the predefined process for each column based on column data. Whereby the predefined process is adapted to each column to obtain the target product and maintain the performance of the liquid chromatography system.

The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.

Allergen

Methods for producing an allergen composition, methods for in vitro diagnosis of type I allergy, and diagnostic kits for performing diagnosis employ Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein. Methods for treatment of a Type I allergy to a mammal and pharmaceutical compositions employ a Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein, wherein the Bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its IgE binding response.

Recombinantly produced allergens

A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having Type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of IgE antibodies specifically binding to the horse allergen, wherein the presence of such IgE antibodies specifically binding to the horse allergen is indicative of Type 1 allergy. A method for treatment of Type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its IgE binding response. The horse allergen may be produced via a vector and a host cell comprising the vector.

Horse allergen and methods

Methods for treatment of a Type I allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its IgE binding response. Diagnostic kits comprise the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support.

Prostate kallikrein allergen

Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient.

The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.

Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.

An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.

Growing community of inventors

Uppsala, Sweden

Lars Mattsson